Os Therapies INC Form 4 insider transactions

Theodore F. Search, a Director and 10% owner of OS Therapies Inc., was granted options to purchase 50,000 shares of common stock.

OS Therapies Inc. Director John Ciccio received a grant of 50,000 stock options with an exercise price of $1.34, vesting in one year.

OS Therapies Inc.'s Chief Financial Officer, Christopher P. Acevedo, was granted 100,000 stock options with a $1.34 exercise price.

OS Therapies' Chief Medical and Scientific Officer, Robert Petit, was granted options to purchase 100,000 shares of common stock at an exercise price of $1.34.

Paul A. Romness, President and CEO of OS Therapies Inc., was granted options to purchase 1,000,000 shares of the company's common stock.

OS Therapies Inc. Director Olivier Roger Jarry received a grant of 50,000 stock options with an exercise price of $1.34, vesting on the one-year anniversary of the grant date.

OS Therapies Inc. Director Karim Galzahr was granted 50,000 stock options with an exercise price of $1.34, vesting in one year.

OS Therapies Inc.'s President and CEO, Paul A. Romness, filed an amended Form 4 to correct the reported number of shares underlying a stock option award granted on October 21, 2025.

OS Therapies Inc. Director and 10% owner Theodore F. Search was granted options to purchase 140,000 shares of common stock at an exercise price of $1.8, vesting in one year.

Robert Petit, Chief Medical Officer and Chief Scientific Officer of OS Therapies Inc., was granted options to purchase 500,000 shares of common stock.

OS Therapies Inc. President and CEO Paul A. Romness was granted 1.95 million stock options with a $1.8 exercise price, vesting in one year.

OS Therapies Inc. Director Olivier Roger Jarry received a grant of 140,000 stock options with an exercise price of $1.80 per share, vesting in one year.

OS Therapies Inc. Director Karim Galzahr was granted 140,000 stock options with an exercise price of $1.80, vesting in October 2026.

OS Therapies Director John Ciccio reports 140,000 stock option grant.

OS Therapies Inc.'s Chief Financial Officer, Christopher P. Acevedo, was granted options to purchase 200,000 shares of common stock at an exercise price of $1.8.

OS Therapies Inc. director Avril McKean-Dieser was granted options to purchase 140,000 shares of common stock, vesting in one year.

Shalom Auerbach and Einodmil LLC ceased being 10% beneficial owners of OS Therapies Inc on May 9, 2025, and are therefore no longer subject to Section 16 reporting requirements.

Shalom Auerbach, a director and 10% owner of OS Therapies Inc, sold 82,000 shares of common stock at an average price of $1.999 per share on May 7, 2025.

Shalom Auerbach, a director and 10% owner of OS Therapies Inc., sold shares of common stock in multiple transactions on April 9th and 10th, 2025.

Paul A. Romness, President and CEO of OS Therapies Inc., received 225,000 shares of common stock from escrow on February 28, 2025, following the terms of a transfer agreement related to the company's initial public offering.

Shalom Auerbach, a director and 10% owner of OS Therapies Inc, forfeited 225,000 shares of common stock on February 27, 2025, according to a recent SEC Form 4 filing.

Shalom Auerbach, a director and 10% owner of OS Therapies Inc, sold 100,000 shares of common stock at an average price of $2.843 per share on February 14, 2025.

A director of OS Therapies Inc., Shalom Auerbach, sold 16,720 shares of common stock at an average price of $6.735 per share.

Shalom Auerbach, a director and 10% owner of OS Therapies Inc, reported the conversion of multiple convertible promissory notes into common stock following the company's initial public offering.

Director Theodore F. Search reports acquisition of shares through conversion of convertible notes held by Mill River Partners LLC upon OS Therapies' initial public offering.

Director John Ciccio reports acquisition of OS Therapies shares through conversion of convertible promissory notes held by Mill River Partners LLC upon the company's initial public offering.